1. Executive Summary and Quick Facts

Saffron is the dried stigma of Crocus sativus L., a sterile triploid member of the iris family (Iridaceae). It is the most labor-intensive and, by weight, one of the most expensive spices in the world, and it is also one of the most researched botanicals in the field of mood, sleep and eye health. Its colour, bitterness and aroma come from three signature molecule families: crocins (colour), picrocrocin (taste) and safranal (aroma). After ingestion, crocins are largely converted to crocetin, the principal circulating metabolite [25,26].

This guide consolidates the botanical, chemical, pharmacological, clinical, safety and quality-control literature on saffron into one reference. It is written for formulators, researchers, clinicians, regulatory professionals, supplement brands and informed consumers. Every section is built so that it can be read independently, but together they form a complete evidence map from field to finished product.

Quick facts at a glance

The evidence in one paragraph

The strongest human data support saffron for improving depressive symptoms in adults with mild-to-moderate depression, where several meta-analyses report effects larger than placebo and, in short head-to-head trials, broadly similar to standard antidepressants [1–4]. Evidence for anxiety, sleep quality, premenstrual syndrome and early age-related macular degeneration is promising but based on fewer, smaller trials [9,10,14–17]. Evidence for weight management, glycaemic control, blood pressure, sexual function and neurodegeneration is preliminary. Most laboratory data on cancer, inflammation and neuroprotection have not yet been translated to patients.

Two cautions apply throughout the literature. First, a large share of clinical trials come from a small number of research groups, often in Iran, which limits generalisability. Second, saffron products differ widely in composition, so results from one extract cannot automatically be applied to another. Authentication and standardisation are therefore not optional extras; they are part of the science.

2. Ingredient Definition and Identity

In commerce, "saffron" means the dried, red stigmatic threads of Crocus sativus flowers. Each flower produces three stigmas, each roughly 25–30 mm long, which are separated from the rest of the flower by hand shortly after picking. The material is then dried and sold either as whole threads or as powder. The name is thought to derive from the Arabic zaʿfarān, which entered European languages through Old French; closely related names appear in Persian, Hindi, Urdu, Spanish and many other languages.

What counts as saffron and what does not

Only the stigma (with, depending on grade, a short piece of style) is saffron in the strict sense used by ISO 3632 and by most pharmacopoeial and food-law definitions. Several other products borrow the name and are not saffron: "Mexican saffron" or "American saffron" usually refers to safflower (Carthamus tinctorius), "Indian saffron" is often turmeric, and "meadow saffron" (Colchicum autumnale) is a different and highly toxic plant. Using these names on a label is a red flag for formulators and consumers.

Commercial forms and trade grades

Trade names reflect how much style remains. Iranian grades include sargol (red tips only, highest colour strength), pushal (red stigma with a small amount of pale style), negin (long, thick, all-red threads) and dasteh (bunched threads including style). Spanish and Italian systems use names such as Coupé, Mancha and Rio. Lower grades contain more yellow style, which carries little colour or flavour. Separately from trade names, ISO 3632 assigns categories I, II and III by laboratory-measured colour, taste and aroma strength (see Section 10).

Other parts of the plant

The tepals (petals) are produced in far greater mass than stigmas and are currently a by-product. They contain flavonoids such as kaempferol glycosides and anthocyanins, and a small number of clinical studies have tested petal extracts, including a pilot trial against fluoxetine [8,44]. The corm is the storage organ used for propagation. Stamens, tepals and corms should never be blended into a product sold as "saffron" without clear declaration.

For scientific writing and labelling, the recommended identity statement is: Crocus sativus L., stigmas (with or without specified proportion of style), authenticated by ISO 3632 testing and, where applicable, a chromatographic fingerprint.

3. Botanical and Chemical Classification

Botanical taxonomy

Crocus sativus is a perennial, corm-forming herb about 10–25 cm tall, with narrow grass-like leaves and lilac to purple flowers made of six tepals. Each flower contains three yellow stamens and a single style that divides into three crimson stigmas. Because the plant is triploid, meiosis is irregular and it produces no viable seed. Every saffron field in the world is therefore propagated vegetatively, by planting daughter corms, and the crop is in practice a set of clonal lineages with limited genetic diversity.

Origin of the species

Cytogenetic and molecular evidence points to Crocus cartwrightianus, native to Greece and the Aegean, as a principal ancestor, with saffron arising as a triploid through a hybridisation or chromosome-doubling event in antiquity; the precise parentage is still debated. This narrow origin is why wild relatives matter for future breeding and why genetic variation between saffron sources is modest compared with the variation in chemical profile caused by environment and processing.

Chemical classification

Saffron's characteristic compounds belong to several chemical classes. Crocins and crocetin are apocarotenoids, derived by oxidative cleavage of the carotenoid zeaxanthin; crocetin is a 20-carbon dicarboxylic acid with a conjugated polyene chain, and crocins are its glycosyl esters. Picrocrocin is a monoterpenoid glycoside, and safranal is a monoterpenoid aldehyde released from picrocrocin. Flavonoids (notably kaempferol derivatives), anthocyanins, phenolic acids and other carotenoids contribute additional biological activity, particularly in the tepals.

Crocin-type pigments are rare in the plant kingdom: they occur in Crocus and in a few other genera, notably Gardenia jasminoides. This shared chemistry has a practical consequence. Because gardenia fruit is a cheap source of crocins, it is one of the most important adulterants of saffron, and simple colour testing cannot distinguish the two [38].

4. Origin, Cultivation and Source

Where saffron is grown

Global production is estimated at several hundred tonnes per year, with Iran, particularly Khorasan province, supplying roughly 90% of the world total. Spain (La Mancha), India (Kashmir), Greece (Kozani), Morocco (Taliouine), Afghanistan, Azerbaijan, Italy and a small but growing number of other countries make up the remainder [40]. Several origins carry protected status, including Spanish Azafrán de La Mancha, Greek Krokos Kozanis and the Italian Zafferano dell'Aquila (all EU PDO) and Kashmir saffron (an Indian geographical indication).

Agronomy

Saffron grows best in a Mediterranean-type climate with hot, dry summers, cool winters, strong sunlight and well-drained, neutral to slightly alkaline soils. Standing water is the main cause of corm rot. Corms are planted in summer at a depth of roughly 10–15 cm, flower in autumn (October–November in the northern hemisphere) and are typically kept in the ground for several years before being lifted, divided and replanted. Yields are commonly a few kilograms of dried spice per hectare, varying sharply with corm size, density, rainfall and field age.

Harvest and labor

Flowers open for only a day or two, and must be picked by hand in the early morning before the tepals open fully, so that stigmas are not damaged by sun and heat. The stigmas are then removed by hand, usually the same day. Roughly 150,000 to 200,000 flowers are needed for one kilogram of dried spice, which translates to several hundred hours of labor per kilogram. This labor intensity, combined with a short harvest window, is the reason for saffron's high price and the main structural incentive for adulteration.

Sourcing variables that change the chemistry

• Environment: altitude, temperature, irrigation and soil influence crocin and picrocrocin content.
• Harvest timing: late or hot-weather picking reduces colour strength.
• Post-harvest drying: drying temperature and speed determine how much safranal forms and how much crocin is lost (Section 9).
• Corm age and genotype: older or poorly managed beds produce lower-yielding flowers.
• Climate pressure: drought and warming are shrinking productive areas in several regions, raising supply risk and price volatility.

For nutraceutical use, the practical implication is simple: two lots of "saffron" can differ several-fold in active-compound content. Origin statements alone do not substitute for assay data.

5. History and Traditional Use

Ancient and classical world

Saffron has one of the longest documented histories of any spice. Bronze Age frescoes from Akrotiri on Santorini, dated to roughly the 17th century BCE, depict figures harvesting crocus stigmas, and Minoan art on Crete shows similar imagery. Saffron appears in Assyrian and Persian records as a dye, perfume and medicine. Greek and Roman writers, including Hippocrates and Dioscorides, describe its use as a remedy, a scent and a luxury colorant, and it was strewn in halls and baths as a symbol of wealth.

Islamic, Ayurvedic and Chinese medicine

In classical Persian and Arabic medicine, including the works of Ibn Sina (Avicenna), saffron was prescribed for mood, digestion, liver and eye complaints and as a general tonic; Avicenna's Canon of Medicine devotes extensive attention to it [31]. In Ayurveda, saffron (kunkuma, kesar) is used as a mood and complexion tonic, a digestive and a reproductive-health herb. In Chinese medicine it is known as fan hong hua or zang hong hua and is used for circulation and menstrual complaints. Across systems, three themes recur: "lifting the spirit", supporting vision and supporting women's health.

Medieval Europe and trade

Saffron cultivation spread through the Islamic world to Spain and later to Italy, France, Switzerland, Germany and England. Demand surged in Europe after plague epidemics, when it was used in medicine and food. The value of the crop is illustrated by the "Saffron War" of 1374, when a shipment was seized near Basel, and by strict adulteration laws in Nuremberg that punished fraud severely. The English town of Saffron Walden takes its name from the crop.

What traditional use does and does not tell us

Traditional use is a source of hypotheses, not proof. The historical emphasis on mood, vision and women's health matches the areas that modern trials have since targeted, which is one reason saffron attracted research attention. However, historical doses were rarely standardised, preparations differed from modern extracts, and traditional claims such as aphrodisiac or anticancer effects remain largely unconfirmed in humans.

6. Modern Nutraceutical Use

Saffron has moved from the kitchen and the apothecary into the dietary-supplement market as a standardised extract or powder, mostly in capsule form. The principal positioning claims, and the strength of evidence behind each, are summarised below.

Saffron is also used as a food colour and flavour, in cosmetics, and in functional foods and beverages. For these uses, culinary quantities (roughly 20–100 mg per serving) deliver much less active material than supplement doses, and no health claim should be implied from culinary use alone.

Market growth has been driven by consumers seeking non-pharmaceutical options for mood, sleep and stress, by the availability of branded, standardised extracts with human trial data, and by interest in eye and cognitive health in ageing populations. The same growth has increased adulteration pressure, making supplier qualification critical.

How brands and clinicians position saffron

In practice, saffron supplements fall into two groups. The first are "mood and stress" products built on trial-tested extracts at roughly 28–30 mg/day. The second are broad "wellness" blends in which saffron is one of many ingredients, frequently at doses far below those studied. For evidence-based formulation, the dose and extract identity should match the trial data being cited. Clinicians who discuss saffron with patients generally frame it as an adjunct for mild symptoms, not as a substitute for established therapy in moderate or severe illness.

7. Chemical Composition

Dried saffron stigma is a complex matrix. On a dry-weight basis, it consists mainly of carbohydrates, with significant protein, minerals, fibre and lipids, and a small but extremely potent fraction of apocarotenoids and volatile compounds. Approximate ranges reported in the literature are given below; actual values vary widely by origin, harvest and processing [22,30].

Why composition is dynamic

Fresh stigmas contain very little free safranal. It forms during drying and storage as picrocrocin is hydrolysed by enzymes and heat, releasing the aglycone that dehydrates to safranal. Conversely, crocins degrade with light, heat, humidity and oxygen, and trans-crocins can isomerise to cis forms. The consequence is that colour, aroma and bitterness change over time even in properly stored product. Storage in the dark, in a sealed container, at low humidity and moderate temperature, preserves potency most effectively.

Biosynthesis in brief

Zeaxanthin is cleaved by carotenoid cleavage dioxygenase 2 (CCD2) to form crocetin dialdehyde and a hydroxylated cyclocitral precursor of picrocrocin [28,39]. The dialdehyde is oxidised to crocetin and then glycosylated by UDP-glucosyltransferases to form crocins; separate enzymatic steps glucosylate the cyclocitral precursor to form picrocrocin. This pathway is relevant to biotechnology: heterologous production of crocins in microbes and other plants is an active research field that could eventually supply pure compounds independent of field harvest.

8. Key Active Compounds

Crocins

Crocins are a family of water-soluble esters of crocetin with one to several glucose, gentiobiose or other sugar units. The most abundant is typically trans-crocin 4 (crocetin di-gentiobiosyl ester), followed by crocins with fewer sugar units. Their conjugated polyene backbone gives saffron its intense golden-orange colour and underlies much of its antioxidant behaviour. Because crocins are large, polar molecules, little intact crocin is absorbed; they function largely as precursors that release crocetin in the gut [25,26].

Crocetin

Crocetin is a 20-carbon apocarotenoid dicarboxylic acid. It is the main compound detected in plasma after oral intake of saffron or crocins, and is the best-studied bioactive in pharmacokinetic work [27]. It has been investigated for effects on oxygen diffusion, neuroprotection, anti-inflammatory activity and metabolic health, and in Japan a pure crocetin ingredient has been studied for sleep and fatigue outcomes.

Picrocrocin

Picrocrocin is responsible for saffron's bitter taste and is the quantitative basis of the "bitterness" parameter in ISO 3632. It is relatively stable in dry conditions but undergoes enzymatic and thermal conversion to safranal. It has been studied less than crocins and safranal for pharmacology, though its role as a marker of authenticity is well established.

Safranal

Safranal gives saffron its characteristic hay-like, slightly medicinal aroma. It is lipophilic and volatile, so it is easily lost during poor storage or high-temperature processing. In animal studies, safranal shows anticonvulsant, anxiolytic, antidepressant and neuroprotective effects, but its content in typical stigma is small and its human pharmacokinetics are poorly characterised [35,38].

Flavonoids and other constituents

Kaempferol glycosides and anthocyanins are concentrated in tepals, and are a plausible contributor to petal-extract activity in trials [8,44]. Minor carotenoids such as zeaxanthin, lycopene and beta-carotene, phenolic acids and the volatile profile add to chemical complexity, though their contribution to clinical effects is unproven.

Active-compound principle: no single compound has been shown to account for all clinical effects. Standardised whole-extract preparations, which retain the natural ratio of crocins, picrocrocin and safranal, have the largest clinical evidence base.

9. Extraction and Processing

Drying: the most important processing step

Freshly separated stigmas contain a large proportion of water and must be dried promptly. Traditional drying uses gentle heat over a charcoal or wood source on a sieve, while modern producers use controlled ovens or dehydrators, commonly in the range of roughly 40–60 °C, though optimum parameters vary. Drying has two simultaneous effects: it lowers moisture to a stable level, and it drives the enzymatic and thermal conversion of picrocrocin to safranal, which creates the characteristic aroma. Excessive heat degrades crocins and volatile compounds; insufficient drying risks mould and enzymatic decline.

Grinding and powdering

Powdered saffron has a larger surface area and is more vulnerable to oxidation, light and humidity. It is also the form most vulnerable to adulteration, since colour, texture and threads can no longer be inspected visually. For nutraceuticals, powders should be ground from authenticated threads and tested after grinding.

Extraction methods

Concentration, drying and encapsulation

Aqueous or hydro-alcoholic extracts are filtered, concentrated under vacuum and often spray-dried with carriers such as maltodextrin to give a free-flowing powder. Because crocins are light- and oxygen-sensitive, finished extracts are best produced under reduced light, packed under inert gas or in barrier packaging, and stabilised by microencapsulation, cyclodextrin complexation or similar technologies. Process parameters (solvent ratio, temperature, time and carrier ratio) determine the final marker profile, which is why two "saffron extracts" are not interchangeable.

Key processing risks: thermal degradation of crocins, loss of safranal, moisture uptake, photodegradation, microbial growth and cross-contamination in shared equipment.

10. Standardization and Potency

ISO 3632: the global spice standard

ISO 3632 defines three quality categories for saffron based on spectrophotometric measurement of an aqueous extract: absorbance near 440 nm (colouring strength, from crocins), near 257 nm (bitterness, from picrocrocin) and near 330 nm (aroma, from safranal) [43]. Higher values indicate higher content. The standard also sets limits for moisture, total ash, acid-insoluble ash, foreign matter and artificial water-soluble acid dyes.

These values are the commonly cited ISO 3632 minima; buyers should consult the current published edition for exact limits, because details have been revised over time. Importantly, the spectrophotometric method measures total absorbance, not individual compounds, and it can be fooled: crocins from gardenia or other sources also absorb at 440 nm.

Chromatographic standardisation

For nutraceuticals, high-performance liquid chromatography (HPLC) with diode-array detection is the preferred approach, because it quantifies individual crocins, picrocrocin and, with appropriate methods, safranal. Specifications are typically expressed as percent crocins, picrocrocin or safranal, or as a total "active marker" sum. Some commercial extracts use proprietary marker terminology; for example, one widely studied extract is described by its manufacturer as standardised to a minimum content of "lepticrosides", a trade-defined marker group. Buyers should ask for the underlying HPLC method and reference standards rather than rely on branded terms alone.

Potency in practice

• Potency should be specified per dose unit (mg of marker per capsule), not only as milligrams of extract.
• Stability testing should track crocins and safranal over shelf life under stated storage conditions.
• Lot-to-lot variability should be controlled by specification limits on both markers and fingerprint profile.
• Dose in clinical trials is expressed as milligrams of stigma or of a specified extract; comparisons across studies require knowing which was used.

11. Mechanisms of Action

Saffron's effects are likely to arise from multiple, overlapping mechanisms rather than a single target. Most mechanistic data come from cell culture and animal models, so the mechanisms below should be read as plausible rather than proven in humans [20,29].

Monoaminergic modulation

Early in vitro and animal studies suggested that saffron extracts and constituents inhibit the reuptake of serotonin, dopamine and norepinephrine, providing a parallel to antidepressant pharmacology [2,33]. However, the potency of reuptake inhibition is modest compared with prescription drugs, which suggests that other mechanisms contribute to clinical effects.

Glutamatergic and GABAergic signalling

Trans-crocetin and saffron extract have been shown to inhibit glutamatergic synaptic transmission, with evidence for NMDA receptor antagonism, in brain-slice experiments [32]. Safranal and crocin appear to modulate GABA-A receptor activity, which would be consistent with anxiolytic and sleep-promoting effects observed in animals [35].

Neurotrophic and stress-axis effects

Animal studies report increased brain-derived neurotrophic factor (BDNF) expression, reduced hypothalamic–pituitary–adrenal (HPA) axis reactivity and improved neurogenesis markers after saffron or crocin administration. These pathways are central to current theories of depression and chronic stress, and offer a mechanistic bridge to mood findings.

Anti-inflammatory and antioxidant actions

Saffron constituents lower pro-inflammatory mediators such as TNF-alpha, IL-1 beta and IL-6 and inhibit nuclear factor kappa B (NF-κB) signalling in many models. They also activate the Nrf2 antioxidant-response pathway and scavenge reactive oxygen species. Neuroinflammation and oxidative stress are implicated in depression, neurodegeneration and retinal disease, so these effects are relevant to several proposed indications.

Amyloid and neurodegeneration

In vitro, crocins and saffron extract inhibit aggregation of amyloid-beta and tau fibrils and show acetylcholinesterase-inhibiting potential [34]. Whether such effects occur at relevant brain concentrations in humans is unknown.

Retinal protection

Animal and clinical retinal studies indicate protection of photoreceptors and retinal pigment epithelium from light-induced damage, anti-apoptotic effects and possible improvement of retinal and choroidal blood flow [14,15].

Metabolic and other pathways

Preclinical work suggests effects on insulin sensitivity, glucose uptake, lipid metabolism (including PPAR and AMPK signalling) and appetite regulation, as well as pro-apoptotic and cell-cycle effects on cancer cell lines [36]. These data justify further clinical research but do not establish clinical efficacy.

Translational caveat: many in vitro experiments use concentrations far above those reachable in human plasma after supplement-level dosing, which is typically in the low micromolar or sub-micromolar range for crocetin.

12. Pharmacokinetics

Absorption

Crocins are not absorbed intact to a meaningful extent. In rats, orally administered crocin showed very low systemic exposure, and in mice both crocin and crocetin led to appearance of crocetin and its glucuronide conjugates in plasma [25,26]. The prevailing model is hydrolysis of crocins to crocetin by intestinal enzymes and gut microbiota, followed by passive absorption of crocetin in the stomach and small intestine.

Distribution

Crocetin circulates bound extensively to serum albumin, which limits free concentration and may affect tissue uptake. Animal studies show distribution to the brain, though blood–brain barrier penetration is limited; retinal and other tissue distribution has been described in preclinical work. Human tissue distribution data are not available.

Metabolism

In addition to hydrolysis, crocetin undergoes phase II conjugation to form mono- and di-glucuronides, and some cis–trans isomerisation. Safranal is metabolised extensively in the liver and has been reported to form safranic acid and conjugates in animals; its human metabolism is poorly described.

Excretion

Crocetin and its conjugates are eliminated in urine and bile. In a healthy-volunteer study of single oral crocetin doses, plasma concentrations peaked within a few hours and fell with an elimination half-life of several hours, consistent with multiple-daily dosing in practice [27].

Implication: because pharmacokinetic data are limited, dose-response relationships in humans are based mainly on trial outcomes, not on exposure targets. Properly designed human PK studies of standardised extracts are a priority.

13. Bioavailability

Bioavailability is a central limitation of saffron actives. Crocins have low oral bioavailability in their native form, and crocetin, while better absorbed, is poorly soluble in water and subject to extensive protein binding and conjugation. These factors may help explain why clinical doses in the tens of milligrams are needed despite apparently high in vitro potency.

Factors that influence bioavailability

• Gut microbiota: conversion of crocins to crocetin depends in part on microbial and intestinal enzymes, which vary between individuals.
• Formulation matrix: lipids and surfactants can improve crocetin solubilisation; polysaccharide carriers affect dispersion.
• Chemical form: pure crocetin is more directly absorbed than crocin, but is less soluble.
• Stability: degradation in gastric fluid and light-driven isomerisation reduce usable dose.
• Food effects: effects of meals on absorption have not been rigorously studied in humans.

Delivery technologies under investigation

Researchers have tested nanoparticles, liposomes, solid lipid carriers, cyclodextrin inclusion complexes, nanoemulsions and phospholipid complexes to improve stability, solubility and absorption of crocin, crocetin and safranal [42]. Many show improved performance in animal or in vitro models, but few have been compared with standard extracts in controlled human trials.

Practical position: for most consumers and formulators, the evidence-based approach is to use a well-characterised, standardised extract at the dose range used in clinical trials, rather than assume that higher-tech delivery systems will be superior without human data.

What this means for dose and product choice

Because absorption of crocetin is incomplete and varies from person to person, the "same" dose of two products can produce different exposure. This is another reason why the clinical dose should always be linked to the specific extract tested, and why apparent non-responders in trials may partly reflect individual differences in gut conversion of crocins. Future studies that measure plasma crocetin alongside clinical outcomes would help determine whether exposure predicts benefit, and whether lower-dose, better-absorbed formulations can match the effect of standard doses.

14. Preclinical Evidence Summary

Preclinical research on saffron is extensive, spanning thousands of in vitro and animal studies. The overall pattern is consistent biological activity at multiple levels, but the quality is variable and translation to humans is incomplete [20,29,36].

Toxicology in animals

Acute toxicity studies show low oral toxicity of saffron stigma extract, with very high lethal doses in rodents, but intraperitoneal toxicity is higher. Subchronic studies at high doses have reported changes in some haematological and biochemical parameters, consistent with the mild changes seen in a human safety study at hundreds of milligrams per day [24,37]. Reproductive toxicology is incompletely characterised, which is why avoidance of medicinal doses in pregnancy is advised.

How to read the preclinical literature

The preclinical evidence provides a rich set of mechanistic hypotheses, but several cautions apply. Many experiments use non-standardised extracts, very high doses or parenteral administration; publication bias is likely; and a significant share of reports come from a limited number of laboratories. Preclinical evidence should therefore be treated as hypothesis-generating, not as proof of human benefit.

15. Human Clinical Evidence Summary

Dozens of randomised controlled trials (RCTs) of saffron have been published. Most are small (often 30–100 participants), short (4–12 weeks) and conducted in Iran, though newer European, Australian and North American trials of standardised extracts are growing. Results are summarised by outcome below.

Depression

Several meta-analyses of RCTs conclude that saffron significantly reduces depressive-symptom scores compared with placebo in adults with mild-to-moderate depression, with large pooled effect sizes but high heterogeneity and risk of bias [1,3,4]. In individual trials, saffron 30 mg/day was reported to be comparable to fluoxetine 20 mg/day and imipramine 100 mg/day over six to eight weeks, with fewer anticholinergic side effects than imipramine [5–7]. A petal-extract pilot trial also reported similar outcomes to fluoxetine [8]. These head-to-head trials were small and not designed to prove non-inferiority formally.

Anxiety and stress

Meta-analytic evidence suggests small to moderate reductions in anxiety symptoms [4]. In healthy adults, a standardised extract improved mood and reduced stress responses in several trials, and in adolescents with mild-to-moderate anxiety and depressive symptoms, a 12-week trial reported benefit on child-reported measures [17–19].

Sleep

A randomised placebo-controlled trial in adults with self-reported poor sleep found that 28 mg/day of a standardised extract for 28 days improved sleep quality scores and insomnia severity compared with placebo [16]. Other studies report small improvements, but replication, objective sleep measurements and longer durations are needed.

Premenstrual syndrome

Saffron 30 mg/day for two menstrual cycles reduced premenstrual symptom scores compared with placebo in a randomised trial [9], and a later trial of a standardised extract reported improvements in premenstrual mood and physical symptoms [10].

Cognition and Alzheimer's disease

In mild-to-moderate Alzheimer's disease, a 22-week trial found saffron 30 mg/day produced cognitive outcomes comparable to donepezil, with less vomiting [11], and a 16-week placebo-controlled trial found superior cognitive scores for saffron [12]. A trial in moderate-to-severe disease found results comparable to memantine [13]. All were small and short, and none shows disease modification.

Eye health

In early age-related macular degeneration, trials found that saffron 20 mg/day improved retinal flicker sensitivity and visual function measures, with benefits sustained during continued use [14]. A later randomised trial reported improved visual acuity in some groups [15]. Larger, longer, independently replicated trials with structural outcomes are still needed.

Appetite and weight

An extract reduced snacking and increased satiety in mildly overweight women over eight weeks, but without consistent weight-loss effects [20]. Other meta-analytic work indicates limited impact on body weight.

Metabolic and cardiovascular risk factors

A systematic review found modest improvements in some cardiovascular risk markers, such as blood pressure or lipids, but with inconsistent results and high heterogeneity [23].

Sexual function

Small trials reported improvements in erectile function in men and in sexual dysfunction associated with fluoxetine in both men and women [21,22]. These pilot studies need replication.

16. Evidence Grading by Outcome

The table below gives an editorial, GRADE-style assessment of the certainty of evidence for each outcome. It is based on the volume, consistency, risk of bias and directness of published trials, not on a formal systematic review. Gradings may change as new trials appear.

A general rule for readers: "moderate" does not mean "proven". It means that further research is likely to affect confidence, and that the estimate of effect is probably close to the truth but may differ substantially.

How the evidence differs by strength of design

• Strongest design signals: placebo-controlled, double-blind RCTs with validated scales, such as those in mild-to-moderate depression and premenstrual syndrome.
• Weaker signals: active-comparator trials without a placebo arm, which cannot show that both treatments beat placebo.
• Weakest signals: single-arm studies, short pilot trials, and trials with surrogate outcomes (for example, flicker electroretinography instead of vision loss progression).

Readers should also consider the independence of the research: trials funded by ingredient suppliers are not inherently invalid, but independent replication is the standard that turns a promising finding into a reliable one.

17. Dosages Used in Studies

These doses refer to the materials used in each study and should not be generalised to all products. A standardised extract with a high marker content cannot be dosed on a milligram-for-milligram basis with a raw powder. For comparison, a culinary pinch typically contains around 20–50 mg of threads, though only part of the colour and flavour compounds is delivered in a meal.

Doses above about 1.2–1.5 g/day have been associated with toxicity and a dose of around 5 g has been reported as potentially lethal; these are not therapeutic ranges and must be avoided [37].

Reading dose data correctly

Three points help avoid misinterpretation. First, dose is not the same as exposure: a product containing 30 mg of low-grade stigma may deliver far less crocin than 30 mg of a standardised extract. Second, no trial has shown that doses above about 30 mg/day are superior for mood outcomes; higher doses mainly increase the chance of adverse effects. Third, there is currently no established minimum effective dose, so claims that a lower dose "works as well" should be treated as unproven unless supported by a dose-comparison trial. For this reason, an upper limit of about 30 mg/day for routine supplement use is a reasonable conservative reference, with any higher use occurring only under professional supervision.

18. Timing and Use

Daily timing

Most trials divided a 30 mg daily dose into two administrations (morning and evening), commonly 15 mg each, while some extract trials used a single daily dose of about 28 mg. Where sleep was the target outcome, evening dosing is logical, but trials have not rigorously compared morning and evening timing. Evidence on food effects is lacking; taking capsules with food is a reasonable approach to reduce nausea.

Time to effect and duration

In mood trials, separation from placebo is commonly reported at two to four weeks, with maximal benefit by six to eight weeks. In sleep trials, benefits were assessed at four weeks. In macular degeneration, improvements in retinal sensitivity were observed after about three months and continued with use. Longer-term benefit and effects of discontinuation are not well characterised.

Practical use principles

• Use consistent daily dosing; effects are not reported to be immediate.
• Choose one authenticated, standardised product and use the studied dose rather than escalating.
• Re-assess benefit after four to eight weeks; discontinue if there is no clear benefit or any adverse effect.
• Do not use saffron to replace prescribed treatment for depression, anxiety or eye disease without medical supervision.

Cycling, stopping and monitoring

There is no evidence that saffron needs to be cycled, and no well-documented withdrawal syndrome, although few trials have followed participants after discontinuation. Users should keep a simple symptom diary (mood, sleep, appetite and any side effects) to judge response objectively. For anyone using saffron alongside prescription treatment, any change in mood, sleep or energy should be reported promptly to the prescriber.

19. Available Forms

The form that matters most is the one with documented composition. A label should state the plant part, extract ratio or type, marker content (for example percent crocins), and milligrams per serving.

Choosing a form for a purpose

For culinary use, whole threads from a supplier who provides ISO 3632 results are ideal; they allow a quick visual check and release flavour well when steeped in warm liquid. For supplement use, a standardised extract with an identifiable manufacturer, a declared marker specification and published human data is preferable. Gummies, drinks and bars are convenient but usually contain too little saffron to match studied doses, so claims on such products should be viewed with caution.

20. Safety and Side Effects

Safety at studied doses

At doses of about 20–30 mg/day for up to several months, saffron has been well tolerated in clinical trials, with adverse-event rates generally similar to placebo [1,3]. In a one-week healthy-volunteer study of 200 mg and 400 mg/day, some mild changes in blood pressure and laboratory parameters were noted, though they remained within normal ranges [24].

Reported side effects

• Gastrointestinal: nausea, vomiting, diarrhoea, abdominal discomfort.
• Neurological and psychological: headache, dizziness, drowsiness, anxiety, agitation, changes in appetite.
• Mouth and dryness: dry mouth.
• Allergic reactions: skin reactions and respiratory symptoms; people allergic to Lolium grasses, Olea (olive) or other Iridaceae pollens may cross-react.
• Mood elevation: hypomania or mania has been theorised or reported in susceptible individuals.

Toxicity at high doses

High doses can cause vomiting, diarrhoea, dizziness, bleeding (such as nasal, vaginal or gastrointestinal), numbness, yellowing of skin and eyes, and, at very high doses (several grams), potentially fatal toxicity [37]. These effects are well outside normal dietary or supplement use.

Who should be cautious

People with bipolar disorder, a history of mania, bleeding disorders, low blood pressure, serious liver or kidney disease, or those scheduled for surgery should seek medical advice before using saffron supplements. Anyone with persistent depressive symptoms, suicidal thoughts or sight changes should seek professional care rather than self-treat.

Long-term safety beyond about six months is not well documented, and there is limited post-marketing surveillance data.

Reporting and risk management

Adverse effects should be reported to a healthcare professional and, where available, to national pharmacovigilance systems. Manufacturers should maintain batch records and complaint-handling processes, since adulteration or contamination can cause adverse events that are wrongly attributed to saffron itself. A frequently overlooked point is that some reported adverse reactions to "saffron" supplements may in fact stem from undeclared adulterants, which again underlines the importance of authenticated material.

21. Drug and Supplement Interactions

Formal clinical interaction studies of saffron are scarce. The following are based on pharmacological plausibility, in vitro data and case-level information, and are best treated as precautionary [37].

Practical advice: anyone taking prescription medicines, particularly psychiatric or cardiovascular drugs, should consult a clinician or pharmacist before starting saffron and report all supplements before surgery.

Managing interaction risk in practice

A sensible approach is to treat saffron like other mood-active botanicals. Avoid starting it on the same day as a new prescription, so that the source of any side effect can be identified. Do not combine it with multiple other serotonergic supplements. Tell every prescriber, dentist and surgeon about saffron use. Review the regimen periodically, since the risk-benefit balance changes when doses of other drugs change.

22. Special Populations

Pregnancy and breastfeeding

Culinary quantities are considered acceptable in food. Medicinal doses are generally advised against in pregnancy because saffron has traditionally been used as an emmenagogue and abortifacient, high doses may stimulate uterine contractions and well-controlled human safety data are absent. Data for lactation are also insufficient; avoiding supplement doses is the cautious position.

Children and adolescents

One RCT of a standardised extract in adolescents aged 12–16 reported benefits and good tolerability over 8 weeks [17], but data in children are very limited. Supplements should be used in minors only under medical supervision.

Older adults

Trials in Alzheimer's disease and age-related macular degeneration involved older adults and reported good tolerability [11,14]. Polypharmacy increases interaction risk and requires clinician review.

Mental health conditions

People with major depression, bipolar disorder, suicidal ideation or on psychiatric medication should use saffron only within a treatment plan supervised by a clinician. Hypomania has been reported in vulnerable people with mood-active agents.

Liver, kidney and cardiovascular disease

There are no dedicated studies in people with hepatic or renal impairment. Because crocetin is eliminated via urine and bile, caution is reasonable. People with low blood pressure or on blood-pressure medication should monitor for additive effects.

Surgery and bleeding risk

Because of theoretical antiplatelet effects, standard practice is to stop non-essential herbal supplements, including saffron extracts, one to two weeks before elective surgery unless the surgeon advises otherwise.

Allergy

People with allergy to saffron or related Iridaceae pollen should avoid saffron.

23. Quality, Testing and Authentication

Quality control for saffron should combine identity, strength, purity and safety testing. No single test is sufficient.

Building a specification

• Identity: botanical name, plant part, authentication method.
• Strength: ISO 3632 category and HPLC marker content.
• Purity: foreign matter, ash, moisture, artificial dye screening.
• Safety: heavy metals (lead, cadmium, arsenic, mercury), pesticide residues, aflatoxins and ochratoxin, microbiological limits, and, for extracts, residual solvents.
• Stability: assay of crocins and safranal across shelf life.

Certificates of analysis should name the method used. A certificate that lists only "ISO 3632 category I" without values, or that shows no HPLC or fingerprint, provides weak assurance.

Supplier qualification

For brands, the most reliable quality control combines supplier audits, retained samples, incoming-lot testing against a written specification, and periodic independent verification by a third-party laboratory. Traceability back to the farm or cooperative, harvest year, and drying and storage conditions allows rapid investigation if a problem emerges. Because adulteration methods evolve, testing programmes should be reviewed regularly and include markers for emerging adulterants.

24. Adulteration and Contamination Risks

Saffron is among the most adulterated foods in the world, because its high price and the visual similarity of cheap substitutes make fraud profitable. Adulteration may be done to increase weight or colour, to mask low quality, or to pass spectrophotometric tests.

Common adulterants

Contamination risks

• Microbiological: poor drying or storage can lead to mould and bacteria such as Salmonella or E. coli.
• Mycotoxins: aflatoxin and ochratoxin risk under humid storage.
• Pesticide residues: depending on agricultural practice.
• Heavy metals: from soil, processing or mineral adulterants.
• Foreign matter and allergens: cross-contamination in shared facilities.

Home tests such as dropping threads in water are only crude indicators. Real saffron releases colour gradually, and threads stay reddish; many fakes bleed colour immediately. Reliable verification requires laboratory analysis and supplier audits.

25. Regulatory Overview

Regulatory status depends on whether saffron is sold as a food, flavouring, colour or supplement, and on jurisdiction. The following is a general overview, and regulations should be checked for each market before launch.

Labelling and claims

Across jurisdictions, claims that a supplement treats, cures or prevents disease are not permitted. Acceptable wording is usually limited to general support for mood, relaxation or normal function, subject to local rules and substantiation. Labels should declare plant part, extract type, marker content, and any cautions for pregnancy, medication use and mood disorders.

Because the authorised status of specific saffron extracts can change, companies should verify with regulators and rely on up-to-date legal advice.

26. Research Gaps

• Large, independent, pre-registered RCTs with sample sizes in the hundreds, in diverse populations, to confirm findings in depression, anxiety, sleep and PMS.
• Longer-term trials (6–12 months or more) that measure relapse, durability, discontinuation effects and long-term safety.
• Dose-ranging studies to identify minimum effective dose and test whether lower doses work.
• Head-to-head formulation comparisons to determine whether stigma, whole extract, petal extract or pure compounds differ in effect.
• Human pharmacokinetics of crocetin, crocins and safranal after repeated dosing of standardised extracts, including food effects and microbiome influence.
• Active-compound attribution to identify which constituents or ratios drive clinical effects.
• Biomarker and mechanistic trials measuring inflammatory markers, BDNF, neuroimaging or retinal imaging endpoints.
• Interaction studies with antidepressants, anticoagulants and CYP substrates.
• Safety in special populations, including pregnancy, lactation, children and renal or hepatic impairment.
• Standard methods for authentication, with shared reference materials and validated rapid tests to curb adulteration.
• Sustainable supply, including tepal valorisation and biotechnological production of crocins.

Closing these gaps would move saffron from a promising botanical with moderate evidence in one area to a well-characterised ingredient with clearly defined uses.

Priorities for the next five years

The highest-value studies would be large, independent, placebo-controlled trials of well-characterised extracts in mild-to-moderate depression and sleep disturbance, combined with human pharmacokinetic sampling, so that clinical response can be tied to measured exposure. In parallel, shared reference standards and validated authentication methods would raise baseline quality across the industry.

27. Frequently Asked Questions (FAQ)

What is saffron and what is it made from?

Saffron is the dried stigma of the Crocus sativus flower. Each flower yields only three stigmas, which are picked and dried by hand, which is why it is so costly.

What are the main active compounds in saffron?

The key compounds are crocins (colour), picrocrocin (bitter taste) and safranal (aroma). After ingestion, crocins are converted mainly to crocetin, the principal circulating metabolite.

What dose of saffron is used in studies?

Most human trials use about 20–30 mg per day of stigma or standardised extract, often split into two doses. This is far above the amount typically eaten in food.

Does saffron really help depression?

Meta-analyses of small to moderate randomised trials report that saffron improves depressive symptoms in adults with mild-to-moderate depression versus placebo. However, trials are short and often from a few research groups, so saffron should not replace professional care.

How long does saffron take to work?

In mood trials, improvements are often reported within two to four weeks, with trials typically running four to twelve weeks. Individual responses vary.

Is saffron safe to take every day?

At about 30 mg/day, trials up to several months report good tolerability, with mild effects such as nausea, headache or dry mouth. Safety beyond that duration, and at higher doses, is less well established.

Can I take saffron with antidepressants?

Not without medical advice. Because saffron may influence serotonin signalling, there is a theoretical risk of additive effects, and clinical interaction data are limited.

Is saffron safe during pregnancy?

Culinary amounts are generally regarded as safe, but medicinal doses are not recommended because high doses have been associated with uterine stimulation and safety data are lacking.

How can I tell if saffron is real?

Look for ISO 3632 certification, whole threads with a trumpet shape, a gradual release of colour in water and a characteristic aroma. Fake saffron often bleeds colour instantly. Laboratory testing is the only definitive method.

What is the best form of saffron to buy?

For supplements, choose an authenticated, standardised extract with marker content and, ideally, human trial data. For cooking, choose whole threads from a reputable seller with a testing certificate.

28. Scientific References

References are numbered to match the bracketed citations in the text. Readers and publishers should verify page ranges and DOIs against the original sources before final publication, and confirm current regulatory texts.

1. Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377-383.
2. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29(6):517-527.
3. Tóth B, Hegyi P, Lantos T, et al. The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Med. 2019;85(1):24-31.
4. Marx W, Lane M, Rocks T, et al. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutr Rev. 2019;77(8):557-571.
5. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005;19(2):148-151.
6. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281-284.
7. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Complement Altern Med. 2004;4:12.
8. Akhondzadeh Basti A, Moshiri E, Noorbala AA, et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439-442.
9. Agha-Hosseini M, Kashani L, Aleyaseen A, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. 2008;115(4):515-519.
10. Lopresti AL, Smith SJ. The effects of a saffron extract (affron) on premenstrual symptoms: a randomized, double-blind, placebo-controlled study. J Womens Health. 2021;30(3):430-439.
11. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology. 2010;207(4):637-643.
12. Akhondzadeh S, Sabet MS, Harirchian MH, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther. 2010;35(5):581-588.
13. Farokhnia M, Shafiee Sabet M, Iranpour N, et al. Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Hum Psychopharmacol. 2014;29(4):351-359.
14. Falsini B, Piccardi M, Minnella A, et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(12):6118-6124.
15. Broadhead GK, Grigg JR, McCluskey P, et al. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial. Graefes Arch Clin Exp Ophthalmol. 2019;257(1):31-40.
16. Lopresti AL, Smith SJ, Metse AP, Drummond PD. Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial. J Clin Sleep Med. 2020;16(6):937-947.
17. Lopresti AL, Drummond PD, Inarejos-García AM, Prodanov M. affron, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: a randomised, double-blind, placebo-controlled study. J Affect Disord. 2018;232:349-357.
18. Kell G, Rao A, Beccaria G, et al. affron a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complement Ther Med. 2017;33:58-64.
19. Jackson PA, Forster J, Khan J, et al. Effects of saffron extract supplementation on mood, well-being, and response to a psychosocial stressor in healthy adults: a randomized, double-blind, parallel group, clinical trial. Front Nutr. 2021;7:606124.
20. Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305-313.
21. Shamsa A, Hosseinzadeh H, Molaei M, Shakeri MT, Rajabi O. Evaluation of Crocus sativus L. (saffron) on male erectile dysfunction: a pilot study. Phytomedicine. 2009;16(8):690-693.
22. Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. 2012;223(4):381-388.
23. Pourmasoumi M, Hadi A, Najafgholizadeh A, Kafeshani M, Sahebkar A. Clinical evidence on the effects of saffron (Crocus sativus L.) on cardiovascular risk factors: a systematic review meta-analysis. Pharmacol Res. 2019;139:348-359.
24. Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers. Phytomedicine. 2008;15(12):1032-1037.
25. Asai A, Nakano T, Takahashi M, Nagao A. Orally administered crocetin and crocins are absorbed into blood plasma as crocetin and its glucuronide conjugates in mice. J Agric Food Chem. 2005;53(19):7302-7306.
26. Xi L, Qian Z, Du P, Fu J. Pharmacokinetic properties of crocin (crocetin digentiobiose ester) following oral administration in rats. Phytomedicine. 2007;14(9):633-636.
27. Umigai N, Murakami K, Ulit MV, et al. The pharmacokinetic profile of crocetin in healthy adult human volunteers after a single oral administration. Phytomedicine. 2011;18(7):575-578.
28. Frusciante S, Diretto G, Bruno M, et al. Novel carotenoid cleavage dioxygenase catalyzes the first dedicated step in saffron crocin biosynthesis. Proc Natl Acad Sci USA. 2014;111(33):12246-12251.
29. Bathaie SZ, Mousavi SZ. New applications and mechanisms of action of saffron and its important ingredients. Crit Rev Food Sci Nutr. 2010;50(8):761-786.
30. Melnyk JP, Wang S, Marcone MF. Chemical and biological properties of the world's most expensive spice: saffron. Food Res Int. 2010;43(8):1981-1989.
31. Hosseinzadeh H, Nassiri-Asl M. Avicenna's (Ibn Sina) the Canon of Medicine and saffron (Crocus sativus): a review. Phytother Res. 2013;27(4):475-483.
32. Berger F, Hensel A, Nieber K. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortico-striatal brain slices. Pharmazie. 2011;66(5):337-344.
33. Wang Y, Han T, Zhu Y, et al. Antidepressant properties of bioactive fractions from the extract of Crocus sativus L. J Nat Med. 2010;64(1):24-30.
34. Papandreou MA, Kanakis CD, Polissiou MG, et al. Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem. 2006;54(23):8762-8768.
35. Pitsikas N. Constituents of saffron (Crocus sativus L.) as potential candidates for the treatment of anxiety disorders and schizophrenia. Molecules. 2016;21(3):303.
36. Samarghandian S, Borji A. Anticarcinogenic effect of saffron (Crocus sativus L.) and its ingredients. Pharmacognosy Res. 2014;6(2):99-107.
37. Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr. 2007;157(13-14):315-319.
38. Carmona M, Zalacain A, Sánchez AM, Novella JL, Alonso GL. Crocetin esters, picrocrocin and its related compounds present in Crocus sativus stigmas and Gardenia jasminoides fruits. J Agric Food Chem. 2006;54(3):973-979.
39. Ahrazem O, Rubio-Moraga A, Nebauer SG, Molina RV, Gómez-Gómez L. Saffron: its phytochemistry, developmental processes, and biotechnological prospects. J Agric Food Chem. 2015;63(40):8751-8764.
40. Cardone L, Castronuovo D, Perniola M, Cicco N, Candido V. Saffron (Crocus sativus L.), the king of spices: an overview. Sci Hortic. 2020;272:109560.
41. Mzabri I, Addi M, Berrichi A. Traditional and modern uses of saffron (Crocus sativus). Cosmetics. 2019;6(4):63.
42. Moratalla-López N, Bagur MJ, Lorenzo C, et al. Bioactivity and bioavailability of the major metabolites of Crocus sativus L. flower. Molecules. 2019;24(15):2827.
43. International Organization for Standardization. ISO 3632-1:2011 Spices — Saffron (Crocus sativus L.) — Part 1: Specification; ISO 3632-2:2010 — Part 2: Test methods.
44. Hosseini A, Razavi BM, Hosseinzadeh H. Saffron (Crocus sativus) petal as a new pharmacological target: a review. Iran J Basic Med Sci. 2018;21(11):1091-1099.
45. U.S. Food and Drug Administration. 21 CFR 73.500 — Saffron (color additives exempt from certification). Code of Federal Regulations.